Can a Cell-Derived vaccine hold lung cancer at bay?

NCT ID NCT01159288

NEW Completed ⭐️ VACCINE ⭐️ Sponsor: Gustave Roussy, Cancer Campus, Grand Paris Source: ClinicalTrials.gov ↗

First seen Aug 17, 2026 · Last updated Aug 17, 2026

Summary

This phase 2 trial tests whether a vaccine made from immune cell-derived exosomes can slow cancer growth in people with advanced non-small cell lung cancer who have responded to initial chemotherapy. Participants receive low-dose cyclophosphamide followed by weekly injections of the exosome vaccine for a month, then biweekly for six weeks. The goal is to see if this approach can improve progression-free survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Tumor antigen-loaded dendritic cell-derived exosomes (Dex) given as intradermal injections, preceded by low-dose cyclophosphamide.
What this could lead to: If successful, this could lead to a new maintenance therapy that delays cancer progression in advanced lung cancer patients who responded to initial chemotherapy.
What could go wrong: This is an early-phase trial with a small number of patients. The vaccine may not boost the immune system enough to slow the cancer, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

Institut Gustave Roussy

Villejuif, 94800, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.